Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
| Autor: | Blanca Serrano-Falcón, Sílvia Delgado-Aros, Fermín Mearin, Constanza Ciriza de los Ríos, Jordi Serra, Miguel Mínguez, Miguel Montoro Huguet, Antonia Perelló, Cecilio Santander, Ángeles Pérez Aisa, Inmaculada Bañón-Rodríguez, Enrique Rey |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Gastroenterology, Vol 12 (2019) |
| Druh dokumentu: | article |
| ISSN: | 1756-2848 17562848 |
| DOI: | 10.1177/1756284819857358 |
| Popis: | Background: Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient population. Methods: In this open-label phase IIIb study, patients with moderate-to-severe IBS-C received linaclotide 290 μg once daily for 12 weeks. The primary endpoint was clinical response at week 12, defined as >30% reduction in IBS symptom severity score (IBS-SSS) or IBS-SSS |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|